21 March 2014 - The links to the Public Summary Documents for the initial rejections from the PBAC meeting held in November 2013 have been added to MAESTrO Australia:

• Adalimumab (Humira)
• Axitinib (Inlyta)
• Crizotinib (Xalkori)
• Multicomponent meningococcal Group B vaccine (Bexsero)
• Ranibizumab (Lucentis)
• Ranibizumab (Lucentis)

Insofar as the PSDs contain a lot more detail on the submissions and their related outcomes than the PBAC short minutes, some aspects of some entries in the MAESTrO Australia database may be edited/revised upon the release of the PSDs. For example, tobramycin (Tobi Podhaler) was recommended on the basis of a cost-benefit analysis (discrete choice experiment); this was not clear in the PBAC short minutes.